ECSP22058286A - Agente profiláctico y/o terapéutico para la prostatitis crónica/síndrome de dolor pélvico crónico - Google Patents
Agente profiláctico y/o terapéutico para la prostatitis crónica/síndrome de dolor pélvico crónicoInfo
- Publication number
- ECSP22058286A ECSP22058286A ECSENADI202258286A ECDI202258286A ECSP22058286A EC SP22058286 A ECSP22058286 A EC SP22058286A EC SENADI202258286 A ECSENADI202258286 A EC SENADI202258286A EC DI202258286 A ECDI202258286 A EC DI202258286A EC SP22058286 A ECSP22058286 A EC SP22058286A
- Authority
- EC
- Ecuador
- Prior art keywords
- chronic
- prophylactic
- therapeutic agent
- pain syndrome
- pelvic pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019233865 | 2019-12-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22058286A true ECSP22058286A (es) | 2022-09-30 |
Family
ID=76575232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202258286A ECSP22058286A (es) | 2019-12-25 | 2022-07-25 | Agente profiláctico y/o terapéutico para la prostatitis crónica/síndrome de dolor pélvico crónico |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12599589B2 (https=) |
| EP (1) | EP4082573A4 (https=) |
| JP (3) | JP7499789B2 (https=) |
| KR (1) | KR20220120646A (https=) |
| CN (2) | CN119303087A (https=) |
| AU (1) | AU2020413313B2 (https=) |
| BR (1) | BR112022012485A2 (https=) |
| CA (1) | CA3165891A1 (https=) |
| CO (1) | CO2022010343A2 (https=) |
| EC (1) | ECSP22058286A (https=) |
| IL (1) | IL294191A (https=) |
| MX (1) | MX2022007936A (https=) |
| PE (1) | PE20230164A1 (https=) |
| PH (1) | PH12022551578A1 (https=) |
| UA (1) | UA130283C2 (https=) |
| WO (1) | WO2021132472A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116082247B (zh) * | 2023-01-19 | 2025-08-01 | 浙江工业大学 | 一种苯并咪唑类衍生物及其应用 |
| CN121401398A (zh) * | 2025-12-29 | 2026-01-27 | 汕头市中心医院 | 一种实验性自身免疫性前列腺炎大鼠模型的构建方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2011023812A1 (en) | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
| WO2011048004A1 (en) * | 2009-10-23 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin e2 synthase-1 |
| TW201206440A (en) * | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
| US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| UY33779A (es) | 2010-12-10 | 2012-07-31 | Boehringer Ingelheim Int | ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas? |
| AR086254A1 (es) | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
| PH12014500326B1 (en) | 2011-08-18 | 2018-01-10 | Nippon Shinyaku Co Ltd | Heterocyclic derivative and pharmaceutical drug |
| CN104039956A (zh) * | 2011-11-04 | 2014-09-10 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 治疗方法 |
| EP3372589B1 (en) * | 2015-10-29 | 2021-10-20 | ASKA Pharmaceutical Co., Ltd. | Pyrimidine derivative |
-
2020
- 2020-12-24 CN CN202411363159.XA patent/CN119303087A/zh active Pending
- 2020-12-24 KR KR1020227025732A patent/KR20220120646A/ko active Pending
- 2020-12-24 EP EP20905872.6A patent/EP4082573A4/en active Pending
- 2020-12-24 WO PCT/JP2020/048479 patent/WO2021132472A1/ja not_active Ceased
- 2020-12-24 AU AU2020413313A patent/AU2020413313B2/en active Active
- 2020-12-24 US US17/788,516 patent/US12599589B2/en active Active
- 2020-12-24 PH PH1/2022/551578A patent/PH12022551578A1/en unknown
- 2020-12-24 PE PE2022001326A patent/PE20230164A1/es unknown
- 2020-12-24 IL IL294191A patent/IL294191A/en unknown
- 2020-12-24 JP JP2021567619A patent/JP7499789B2/ja active Active
- 2020-12-24 MX MX2022007936A patent/MX2022007936A/es unknown
- 2020-12-24 UA UAA202202629A patent/UA130283C2/uk unknown
- 2020-12-24 CN CN202080090316.8A patent/CN114867495B/zh active Active
- 2020-12-24 CA CA3165891A patent/CA3165891A1/en active Pending
- 2020-12-24 BR BR112022012485A patent/BR112022012485A2/pt unknown
-
2022
- 2022-07-22 CO CONC2022/0010343A patent/CO2022010343A2/es unknown
- 2022-07-25 EC ECSENADI202258286A patent/ECSP22058286A/es unknown
-
2024
- 2024-06-04 JP JP2024090606A patent/JP7779953B2/ja active Active
-
2025
- 2025-11-19 JP JP2025199177A patent/JP2026015542A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024103724A (ja) | 2024-08-01 |
| JP2026015542A (ja) | 2026-01-29 |
| MX2022007936A (es) | 2022-10-27 |
| PE20230164A1 (es) | 2023-02-01 |
| CA3165891A1 (en) | 2021-07-01 |
| BR112022012485A2 (pt) | 2022-09-06 |
| AU2020413313B2 (en) | 2025-11-27 |
| EP4082573A4 (en) | 2024-01-10 |
| JPWO2021132472A1 (https=) | 2021-07-01 |
| NZ789736A (en) | 2025-10-31 |
| CO2022010343A2 (es) | 2022-10-31 |
| JP7779953B2 (ja) | 2025-12-03 |
| US12599589B2 (en) | 2026-04-14 |
| US20230094705A1 (en) | 2023-03-30 |
| CN114867495A (zh) | 2022-08-05 |
| AU2020413313A1 (en) | 2022-07-14 |
| JP7499789B2 (ja) | 2024-06-14 |
| PH12022551578A1 (en) | 2023-11-29 |
| WO2021132472A1 (ja) | 2021-07-01 |
| EP4082573A1 (en) | 2022-11-02 |
| CN119303087A (zh) | 2025-01-14 |
| KR20220120646A (ko) | 2022-08-30 |
| UA130283C2 (uk) | 2026-01-07 |
| CN114867495B (zh) | 2024-10-18 |
| IL294191A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| MX391859B (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres | |
| MX2019014041A (es) | Inhibidores pirazolicos de magl. | |
| SA519400913B1 (ar) | تركيبة موضعية لتعزيز إلتئام الجروح | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| MX2019014772A (es) | Formulaciones en gel de bisfosfocinas y usos de estas. | |
| BR112018016729A2 (pt) | novo composto de tiofeno substituído nas posições 2,3,5, utilizado como inibidor de proteína quinase | |
| CR20190536A (es) | Inhibidores pirazólicos de magl | |
| CO2021003103A2 (es) | Composiciones oleaginosas tópicas | |
| PE20211599A1 (es) | Administracion prolongada de lasmiditan por la noche para la prevencion de la migrana | |
| ECSP22058286A (es) | Agente profiláctico y/o terapéutico para la prostatitis crónica/síndrome de dolor pélvico crónico | |
| CL2009000660A1 (es) | Uso de un antagonista del receptor 2 activado con proteasa (par2) para tratar, inhibir o aliviar el dolor. | |
| EP4616848A3 (en) | Linezolid formulations | |
| PH12020500510A1 (en) | Prophylactic and/or therapeutic agent for diseases involving ido expression | |
| MX394833B (es) | Formulaciones con mejora de la estabilidad. | |
| MX390899B (es) | Formulación de combinación de dosis fija, eflornitina y sulindaco. | |
| AR109407A1 (es) | Compuesto de 1-acetil-3-fenilurea y su uso | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| AR109406A1 (es) | Compuesto de 1-fenil-3-carbamoilurea y su uso | |
| CO2020001881A2 (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco trometamina y clorhidrato de tramadol | |
| PH12018501991A1 (en) | Pharmaceutical composition for use in treating fibrosis | |
| EP4389128A4 (en) | DRUG ASSOCIATION | |
| MX393608B (es) | Profilactico o agente terapeutico para queratitis fungica. | |
| SV2016005308A (es) | Composiciã“n farmacã‰utica para el tratamiento de alopatã�as relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol | |
| MX2017008879A (es) | Composicion farmaceutica para el tratamiento de la micosis. |